Compare DexCom, Inc. (DXCM) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Microchip Technology Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Microchip Technology Inc. trades at $75.55 (market cap $41.01B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.41% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Microchip Technology Inc. for 63 Days on average.
| DXCM | MCHP | |
|---|---|---|
Market Cap | $31.86B | $41.01B |
Volume | 3,607,070 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $92.34 | $102.97 |
52-Week Low | $54.84 | $49.02 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $31.32B | $46.13B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MCHP trades at $75.52, down 3.2% over 24 hours, with technical indicators showing a bearish trend. The company reported a net loss of -$500K in 2025, though it has consistently beaten EPS estimates in recent quarters. Recent news highlights expansion in Ethernet and 48V power portfolios, including the acquisition of Hailo, targeting automotive and industrial demand. Analyst consensus is strongly bullish with a $110.50 price target, but high valuation ratios and significant debt pose risks.
The outlook is mixed: strong analyst support and strategic expansions in AI and data centers offer growth potential, but high P/E of 111.06 and net income margin pressure from 2025 raise concerns. Investors face upside from earnings beats and sector demand against valuation and cyclical semiconductor risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
